ORPHA:2023
Undifferentiated pleomorphic sarcoma
Also known as: UPS
Publications
13,302
98th percentile
Trials
58
Interventional, condition-specific
Researchers
1,229
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
An aggressive sarcoma of soft tissues or bone that can arise from any part of the body, clinically presenting as swelling, mass, pain, pathological fracture and occasional systemic features and is characterized by high local recurrence and significant metastasis.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0002142
- MeSH:D051677
- UMLS:C0334463
- NCIT:C114541
- NCIT:C4247
Additional Mondo synonyms (22)
MFH · Storiform-pleomorphic MFH · Storiform-pleomorphic fibrous histiocytoma · Storiform-pleomorphic malignant fibrous histiocytoma · Unclassified Pleomorphic sarcoma (formerly "MFH") · Unclassified Pleomorphic sarcoma (formerly "malignant fibrous histiocytoma") · adult malignant fibrous histiocytoma · adult unclassified pleomorphic sarcoma · adult undifferentiated pleomorphic sarcoma · fibrous histiocytoma, malignant · fibrous histiocytoma, malignant (morphologic abnormality) · fibroxanthosarcoma · fibroxanthosarcoma (morphologic abnormality) · histiocytoma, fibrous, malignant · malignant fibrous cytoma · malignant fibrous histiocytoma · malignant fibrous histiocytoma of soft tissue and bone · malignant fibrous histiocytoma of the soft tissue and bone · malignant fibroxanthoma · unclassified pleomorphic sarcoma · undifferentiated pleomorphic sarcoma · undifferentiated pleomorphic soft tissue sarcoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
13,302 matched papers (6,323 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
58 matched on ClinicalTrials.gov (12 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
13,302
13,302 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
13,302 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
6,323 in the last 10 years · medium confidence · 98th percentile (publications denominator)
Phrase hits: 13,302 · MeSH hits: 0
Who's working on it?
1,229
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Chen X5 papers · 2026
Health Management Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Papers in Europe PMC - 02Li Y5 papers · 2026
Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China.
Papers in Europe PMC - 03Hayashi K4 papers · 2025
Department of Orthopaedic Surgery, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.
Papers in Europe PMC - 04Zhang L4 papers · 2026
Department of Radiation Oncology, the First Affiliated Hospital of Anhui Medical University, No. 218, Jixi Road, Hefei, Anhui, 230022, People's Republic of China.
Papers in Europe PMC - 05Demura S3 papers · 2025
Department of Orthopedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-Machi, Kanazawa, 920-8640, Japan.
Papers in Europe PMC - 06Fetisov TI3 papers · 2025
Research Institute of Molecular and Cellular Medicine, Peoples' Friendship University of Russia (RUDN University), 115093 Moscow, Russia.
Papers in Europe PMC - 07Galoaa BM3 papers · 2026
Orthopaedic Oncology Service, Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, BostonBoston, MA, USA.
Papers in Europe PMC - 08Girgis AG3 papers · 2026
Orthopaedic Oncology Service, Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, BostonBoston, MA, USA.
Papers in Europe PMC - 09Gonzalez MR3 papers · 2026
Orthopaedic Oncology Service, Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, BostonBoston, MA, USA.
Papers in Europe PMC - 10Kawai A3 papers · 2025
Division of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
58
interventional trials for this specific condition
58 interventional trials matched this specific condition name; 12 currently recruiting in our sample. 1,600 trials are registered for sarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
58 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 97.3th percentile).
medium confidence · 97.3th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
58 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04055220·RECRUITING·Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Conditions: Bone Sarcoma · Osteosarcoma · Ewing Sarcoma · Chondrosarcoma·Matched via name phrase
- NCT05961761·RECRUITING·Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
Conditions: Soft Tissue Sarcoma Adult · Angiosarcoma · Undifferentiated Pleomorphic Sarcoma·Matched via name phrase
- NCT06789172·RECRUITING·A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Conditions: Solid Tumours · Sarcoma · HNSCC · Non Small Cell Lung Cancer·Matched via name phrase
- NCT05711615·RECRUITING·Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Conditions: Metastatic Dedifferentiated Liposarcoma · Metastatic Leiomyosarcoma · Metastatic Myxofibrosarcoma · Metastatic Sarcoma·Matched via name phrase
- NCT06277154·RECRUITING·MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Conditions: Leiomyosarcoma · Liposarcoma · Synovial Sarcoma · Angiosarcoma·Matched via name phrase
- NCT05182164·RECRUITING·Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
Conditions: Soft Tissue Sarcoma Adult · Advanced Soft-tissue Sarcoma · Ewing Sarcoma · Osteosarcoma·Matched via name phrase
- NCT07173972·RECRUITING·Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.
Conditions: Soft Tissue Sarcoma (STS) · Soft Tissue Sarcoma Adult · Soft Tissue Sarcoma of the Trunk and Extremities · Synovial Sarcomas·Matched via name phrase
- NCT07169344·RECRUITING·Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
Conditions: Soft Tissue Sarcoma (Excluding GIST) · Soft Tissue Sarcoma Adult · Soft Tissue Sarcoma of the Trunk and Extremities · Synovial Sarcomas·Matched via name phrase
- NCT06422806·RECRUITING·Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Conditions: Metastatic Dedifferentiated Liposarcoma · Metastatic Undifferentiated Pleomorphic Sarcoma · Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 · Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8·Matched via name phrase
- NCT05607095·RECRUITING·A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
Conditions: Uveal Melanoma · Melanoma · Metastatic Uveal Melanoma · Metastatic Melanoma·Matched via name phrase
- NCT06526897·NOT YET RECRUITING·Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma
Conditions: Adult Pleomorphic Rhabdomyosarcoma · AJCC Grade 2 Sarcoma · AJCC Grade 3 Sarcoma · Alveolar Soft Part Sarcoma·Matched via name phrase
- NCT04332874·RECRUITING·A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
Conditions: Sarcoma · Myxofibrosarcoma · Undifferentiated Pleomorphic Sarcoma · Alveolar Soft Part Sarcoma·Matched via name phrase
Broader category: sarcoma
1,600
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07359053·RECRUITING·MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma
Conditions: Sarcoma·Matched via name phrase
- NCT06805773·RECRUITING·Evaluating the Use of Educational Videos in Newly Diagnosed Patients in a Medical Oncology Sarcoma Clinic
Conditions: Sarcoma·Matched via name phrase
- NCT07460986·NOT YET RECRUITING·A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA
Conditions: Sarcoma of Soft Tissue·Matched via name phrase
- NCT07134192·RECRUITING·Fluorescence-Guided Optimization of Sarcoma Margins
Conditions: Soft Tissue Sarcoma of the Trunk and Extremities · Sarcoma·Matched via name phrase
- NCT01659203·RECRUITING·Proton or Photon RT for Retroperitoneal Sarcomas
Conditions: Retroperitoneal Sarcoma·Matched via name phrase
- NCT07032285·RECRUITING·Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas
Conditions: Soft Tissue Sarcoma (STS)·Matched via name phrase
- NCT07308886·RECRUITING·Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
Conditions: Kaposi Sarcoma·Matched via name phrase
- NCT06789666·RECRUITING·Digital Art Therapy for Young Cancer Survivors
Conditions: Cancer · Pediatric Cancer · Pediatric Malignancies · Pediatric Sarcoma of Soft Tissue·Matched via name phrase
- NCT07052383·RECRUITING·Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
Conditions: Osteosarcoma · Soft Tissue Sarcoma·Matched via name phrase
- NCT06066138·RECRUITING·A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Conditions: Locally Advanced Alveolar Soft Part Sarcoma · Metastatic Alveolar Soft Part Sarcoma · Locally Advanced Non Small Cell Lung Cancer · Metastatic Non Small Cell Lung Cancer·Matched via name phrase
- NCT06498648·RECRUITING·Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Conditions: Advanced Dedifferentiated Liposarcoma · Advanced Leiomyosarcoma · Advanced Soft Tissue Sarcoma · Metastatic Dedifferentiated Liposarcoma·Matched via name phrase
- NCT05918640·RECRUITING·Lurbinectedin in FET-Fused Tumors
Conditions: Ewing Sarcoma · Desmoplastic Small Round Cell Tumor · Pediatric Cancer · Undifferentiated Sarcoma·Matched via name phrase
- NCT06371768·RECRUITING·Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
Conditions: Cancer · Breast Cancer · Colorectal Cancer · Sarcoma·Matched via name phrase
- NCT04698785·RECRUITING·Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
Conditions: Bone Sarcoma · Osteosarcoma·Matched via name phrase
- NCT04758000·RECRUITING·Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse
Conditions: Osteosarcoma · Ewing Sarcoma·Matched via name phrase
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05515068·NOT YET RECRUITING·Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
Conditions: Osteosarcoma · Bone Tumor · Bone Sarcoma · High Grade Sarcoma·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Undifferentiated pleomorphic sarcoma" OR "Storiform-pleomorphic MFH" OR "Storiform-pleomorphic fibrous histiocytoma" OR "Storiform-pleomorphic malignant fibrous histiocytoma" OR "Unclassified Pleomorphic sarcoma (formerly MFH)" OR "Unclassified Pleomorphic sarcoma (formerly malignant fibrous histiocytoma)" OR "adult malignant fibrous histiocytoma" OR "adult unclassified pleomorphic sarcoma" OR "adult undifferentiated pleomorphic sarcoma" OR "fibrous histiocytoma, malignant" OR "fibrous histiocytoma, malignant (morphologic abnormality)" OR "fibroxanthosarcoma" OR "fibroxanthosarcoma (morphologic abnormality)" OR "histiocytoma, fibrous, malignant" OR "malignant fibrous cytoma" OR "malignant fibrous histiocytoma" OR "malignant fibrous histiocytoma of soft tissue and bone" OR "malignant fibrous histiocytoma of the soft tissue and bone" OR "malignant fibroxanthoma" OR "unclassified pleomorphic sarcoma" OR "undifferentiated pleomorphic soft tissue sarcoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Undifferentiated pleomorphic sarcoma" OR "Storiform-pleomorphic MFH" OR "Storiform-pleomorphic fibrous histiocytoma" OR "Storiform-pleomorphic malignant fibrous histiocytoma" OR "Unclassified Pleomorphic sarcoma (formerly MFH)" OR "Unclassified Pleomorphic sarcoma (formerly malignant fibrous histiocytoma)" OR "adult malignant fibrous histiocytoma" OR "adult unclassified pleomorphic sarcoma" OR "adult undifferentiated pleomorphic sarcoma" OR "fibrous histiocytoma, malignant" OR "fibrous histiocytoma, malignant (morphologic abnormality)" OR "fibroxanthosarcoma" OR "fibroxanthosarcoma (morphologic abnormality)" OR "histiocytoma, fibrous, malignant" OR "malignant fibrous cytoma" OR "malignant fibrous histiocytoma" OR "malignant fibrous histiocytoma of soft tissue and bone" OR "malignant fibrous histiocytoma of the soft tissue and bone" OR "malignant fibroxanthoma" OR "unclassified pleomorphic sarcoma" OR "undifferentiated pleomorphic soft tissue sarcoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 58 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"sarcoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: UPS; MFH
Confidence reasoning
- Preferred label is multi-word and distinctive
- 2 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T18:46:54.536Z
